N-[2-(5-bromo-1-indolinyl)phenyl]-4-methyl-1-piperazinecarboxamide → 4-Bromo-6-(4-methyl-1-piperazinyl)-1,2dihydrobenzo[b]pyrrolo[3,2,1-jk][1,4]benzodiazepine
反応式
[Br:1][C:2]1[CH:3]=[C:4]2[C:8](=[CH:9][CH:10]=1)[N:7]([C:11]1[CH:16]=[CH:15][CH:14]=[CH:13][C:12]=1[NH:17][C:18]([N:20]1[CH2:25][CH2:24][N:23]([CH3:26])[CH2:22][CH2:21]1)=O)[CH2:6][CH2:5]2>P(Cl)(Cl)(Cl)=O>[Br:1][C:2]1[CH:3]=[C:4]2[CH2:5][CH2:6][N:7]3[C:8]2=[C:9]([CH:10]=1)[C:18]([N:20]1[CH2:25][CH2:24][N:23]([CH3:26])[CH2:22][CH2:21]1)=[N:17][C:12]1[CH:13]=[CH:14][CH:15]=[CH:16][C:11]=13参加物
実験手順
A mixture of N-[2-(5-bromo-1-indolinyl)phenyl]-4-methyl-1-piperazinecarboxamide (11.5 g, 27.5 mmoles) and 750 ml of phosphorus oxychloride was stirred until a solution was obtained and then heated under reflux for 40 minutes. The reaction mixture was cooled. Excess phosphorus oxychloride was removed by evaporation at 50°-55° C. The residue was dried for 30 minutes under vacuum. Ice-chilled 2N sodium hydroxide solution (250 ml) and dichloromethane (350 ml) were added to the residue at 4° C. (ice-water bath). The mixture was stirred until all the solid had dissolved. The organic phase was separated and washed with brine (2 times, 200 ml), dried over anhydrous magnesium sulfate and concentrated. Crystallization from ether (100 ml) gave 5.7 g (57%) of product. Recrystallization from isopropanol yielded the analytical sample, mp 203°-204° C.
後処理
- customwas obtained
- temperatureheated
- temperatureunder reflux for 40 minutes
- temperatureThe reaction mixture was cooled
- customExcess phosphorus oxychloride was removed by evaporation at 50°-55° C
- customThe residue was dried for 30 minutes under vacuum
- temperatureIce-chilled 2N sodium hydroxide solution (250 ml) and dichloromethane (350 ml)
- additionwere added to the residue at 4° C. (ice-water bath)
- stirringThe mixture was stirred until all the solid
- dissolutionhad dissolved
- customThe organic phase was separated
- washwashed with brine (2 times, 200 ml)
- dry with materialdried over anhydrous magnesium sulfate
- concentrationconcentrated
- customCrystallization from ether (100 ml)
出典と根拠
- ORDレコード
- ord-e21dae76eb054e48bb6f93275e400669
- 出典データセット
- uspto-grants-1988_02
- 特許番号
- US04723007
反応ノート
読み込み中…